Induction platinum-based chemotherapy followed by radical hyperfractionated radiotherapy with concurrent chemotherapy in the treatment of locally advanced non-small-cell carcinoma of the lung

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 22, Issue 2, 1999, Pages 203-208

  Lopez Picazo, J M ^a   Azinovic, I ^a,c   Aristu, J J ^a   Monge, R Martinez ^a   Jimenez, M Moreno ^a   Aller, E Calvo ^a   Beltran, C ^a   Aramendia, J M ^a   Rebollo, J ^b   Brugarolas, A ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b Clinica San Miguel   (Spain)

^c Clinica Universitaria   (Spain)

Author keywords

Chemotherapy; Combined therapy; Locally advanced non small cell lung cancer; Radical hyperfractionated radiotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; NAVELBINE; PACLITAXEL; PLATINUM;

ADOPTIVE IMMUNOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LYMPHOKINE ACTIVATED KILLER CELL; MALE; NEUTROPENIA; RADIATION DOSE; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOTHERAPY DOSAGE; SURVIVAL ANALYSIS; TREATMENT FAILURE;

EID: 0033503010     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199904000-00023     Document Type: Article

References (34)

1. Damstrup L, Poulsen HS. Review of the curative role of radiotherapy in the treatment of non-small-cell lung cancer. Lung Cancer 1994;11:153-78.
2. Perez CA, Pajak TF, Rubin P, et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definite radiotherapy. Report by the Radiation Oncology Group. Cancer 1987;59:1874-81.
3. Perez CA, Stanley H, Rubin P, et al. A prospective randomized study of various radiation doses and fractionation schedules in the treatment of inoperable non-oat cell carcinoma of the lung. Cancer 1980;45:2744-53.
4. Robertson JM, Ten Haven RK, Hazuka MB, et al. Dose escalation for non-small-cell lung cancer using conformal radiation therapy. Int J Radiat Oncol Biol Phys 1997;37:1079-85.
5. Cote RJ, Beattie EJ, Chaiwun B, et al. Detection of occult bone marrow micrometastases in patients with operable lung carcinoma. Ann Surg 1995;222:415-23.
6. Cox JD, Azarnia N, Byhardt RW, Shin KH, Emami B. Pajak TF. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma. Report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 1990;8:1543-55.
7. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990;323:940-5.
8. Dillman RO, Hemdon J, Seagren SL. Eaton WL. Green MR. Improved survival in stage III non-small-cell lung cancer: sevenyear follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 1996;88:1210-5.
9. Sause WT, Scott C, Taylor S, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995;87:198-205.
10. Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991;83:417-23.
11. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992;326:524-30.
12. Jeremic B, Shibamoto Y, Acimovic L. Djuric L. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 1997;13:452-8.
13. Soresi E, Clerici M, Grilli R. A randomized clinical trial comparing radiation therapy vs radiation therapy plus cis-dichlorodiamin platinum (II) in the treatment of locally advanced non-small-cell lung cancer. Semin Oncol 1988;15:20-5.
14. American Joint Committee on Cancer (AJCC). Manual for staging of cancer. 4th ed. Philadelphia: JB Lippincott. 1987.
15. Kaplan EI, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
16. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966: 50:163-70.
17. Martel MK. Ten Haken RK. Hazuza MB, Turrisi AT. Fraass BA. Lichter AS. Dose-volume histogram and 3-D treatment planning evaluation of patients with pneumonitis. Int J Radiat Oncol Biol Phys 1994;28:575-81.
18. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
19. Martel MK, Strawderman M, Hazuka MB, Turrisi AT, Fraass BA. Lichter AS. Volume and dose parameters for survival of non-small-cell lung cancer patients. Radiother Oncol 1997;44:23-9.
20. Curran WJ, Cox JD. Azarnia N, et al. Comparison of the Radiation Therapy Oncology Group and American Joint Committee on Cancer staging systems among patients with non-small-cell lung cancer receiving hyperfractionated radiation therapy. A report of the Radiation Therapy Oncology Group protocol 83-11. Cancer 1991;68:509-16.
21. Marino P, Preatoni P, Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb non-small-cell lung cancer: a meta-analysis. Cancer 1995;76:593-601.
22. Brittell JC, Eagan T, Ingle N. Cis-dichlorodiammineplatinum alone followed by adriamycin plus cyclophosphamide at progression versus cis-dichlorodiammineplatinum, adriamycin, and cyclophosphamide in combination for adenocarcinoma of the lung. Cancer Treat Rep 1978;62:1207-10.
23. Longeval E, Klastersky J. Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma. Cancer 1982;50:2751-6.
24. Murphy WK, Fossella FV, Winn RJ, et al. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 1993;85:384-8.
25. Depierre A, Lemarie E, Dabouis G, Garnier G, Jacoulet P, Dalphin JC. A phase II study of navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. Am J Clin Oncol 1991;14:115-9.
26. Francis PA, Rigas JR, Kris MG, et al. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 1994;12:1232-7.
27. Gatzemeier U, Shepherd FA. Le Chevalier T, et al. Activity of gemcitabine in patients with non-small-cell lung cancer: a multicentre, extended phase II study. Eur J Cancer 1996;32A:243-8.
28. Fukuoka M, Niitani H, Suzuki A, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 1992;10:16-20.
29. Crino L, Scagliotti G, Marangolo M, et al. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1997;15:297-303.
30. Masuda N, Fukuoka M, Takada M, et al. CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 1992;10:1775-80.
31. Langer CJ, Leighton J, McAleer C, Comis R, O'Dwyer P, Ozols R. Paclitaxel and carboplatin in the treatment of advanced non-small-cell lung cancer. Semin Oncol 1995;22:64-9.
32. Kimura H, Yamaguchi Y. A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Cancer 1997;80:42-9.
33. Calvo FA, Ortiz de Urbina D, Abuchaibe O. et al. Intraoperative radiotherapy during lung cancer surgery: technical description and early clinical results. Int J Radiat Oncol Biol Phys 1990;19:103-9.
34. Aristu J, Rebollo J, Martinez-Monge R, et al. Cisplatin, mitomycin, and vindesine followed by intraoperative and postoperative radiotherapy for stage III non-small-cell lung cancer: final results of a phase II study. Am J Clin Oncol 1997;20:276-81.